Skip to main content

Home/ health information/ Group items tagged pharmaceutical-sector-R&D-investment

Rss Feed Group items tagged

pharmacybiz

Pharmaceutical Sector Leads in R&D Investment | Latest Industry News 2024 - 0 views

  •  
    UK businesses invested £50 billion in research and development (R&D) in 2023, according to the annual survey report released by the Office for National Statistics (ONS). This marks a £1.4 billion increase (2.9%) compared to the previous year's £48.5 billion. Pharmaceuticals remained the largest contributor to business R&D spending, with £8.7 billion allocated to the sector, accounting for 17.4% of the total R&D expenditure by UK businesses. However, this is slightly down from £8.8 billion in 2022. Other major contributors among product groups included software development with R&D spending at £7.6 billion, and miscellaneous business activities such as technical testing and analysis at £6.9 billion. When measuring the value of R&D performed by industry, the scientific research and development industry emerged as the top performer, with £12.7 billion spent, representing 25.3% of total business R&D.
pharmacybiz

UK must swiftly fend off competition | Life sciences Vision - 0 views

  •  
    The UK must act swiftly to fend off competition if it wants to build the world's leading life sciences sciences hub, a new report suggests. A year on from the launch of the government's life science vision, the report commissioned by the the Association of the British Pharmaceutical Industry said although achieving the ambition remained feasible, the UK would need an attractive business environment because its competitor countries were becoming more adept at attracting investment. To achieve the ambition of the vision, the PwC-produced report suggested raising pharmaceutical R&D investment in the UK to build a 'stronger manufacturing and research infrastructure', alongside better investment in, access to and uptake of innovative medicines. It said the UK would also need to adopt a renewed approach to the priority healthcare challenges identified in the government's 'Life Science Vision', which would mean cutting the overall burden on health of dementia, cancer, cardiovascular and respiratory disease and mental health. The report quantified the size of the prize if the vision was implemented in full and the UK could emulate the successes of leading EU countries, which included: £68 billion in additional GDP over 30 years, owing to increased R&D investment £16.3 billion additional annual GDP from increased pharmaceutical exports Supporting 85,000 additional jobs Up to 40 per cent decrease in disease burden across the whole UK - for areas like cardiovascular disease, mental health conditions and Cancer. Reduced variation in speed of access to new medicines within three months of licensing for all NHS patients.
pharmacybiz

"Meaningful Investment" For The UK's Life Science Vision - 0 views

  •  
    In its submission to the Treasury ahead of the Comprehensive Spending Review this autumn, the Association of the British Pharmaceutical Industry (ABPI) says it is essential for the government to deliver "meaningful investment" for the UK's Life Science Vision. Richard Torbett, chief executive of the ABPI, has written to the UK's chancellor of the Exchequer, Rishi Sunak, making a case for investing in the life sciences sector while stressing on the contribution it has made to global public health during the pandemic. The government's pledge to invest £22 billion per year in R&D by the end of this parliament is an essential foundation for life sciences growth, but the sector also needs the right incentives to encourage private business investment, it said.
1 - 3 of 3
Showing 20 items per page